Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. (FENC) Stock Overview
Explore Fennec Pharmaceuticals Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
229.2M
P/E Ratio
-16.50
EPS (TTM)
$-0.53
ROE
5.90%
FENC Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Fennec Pharmaceuticals Inc. (FENC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $6.27.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -16.50 and a market capitalization of 229.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Jeffrey S. Hackman
32
68 TW Alexander Drive, Research Triangle Park, NC
2017